Pharma Focus Asia

Statistical Designs for Assessing Interchangeability of Biosimilar Products

China Lu Y, College of Applied Sciences, Beijing University of Technology, Beijing,Chow SC, Duke University School of Medicine, Durham, North Carolina, USAZhang ZZ, College of Applied Sciences, Communication University of China, Beijing, China

More and more biopharmaceutical and/or biotech companies begin to concern regulatory approval of biosimilar products, due to some innovator products will expire in decades. Once more biological products are going off patient, the problem whether approving biosimilar products used interchangeably and safely will be considered. Using a biological product of the reference product interchangeably, the United States Food and Drug Administration (FDA) requires that, for a biological product that is administered more than once to an individual, the risk in terms of safety or diminished efficacy of alternating or switching between the use of the biological product and the reference product, is not greater than the risk of using the reference product without such alternation or switch. For this purpose, based on the concept of switching and/or alternation several useful designs for assessing drug interchangeability are proposed. In addition, by developed biosimilarity index, a uni?ed approach is discussed. The proposed method is robust against biosimilarity criteria and is applicable under a valid and appropriate study design.

Corresponding Author :

Lu Y
College of Applied Sciences
Beijing University of Technology
Beijing, China
E-mail: zhtongl@hotmail.com

 

Received July 22, 2013; Accepted September 20, 2013; Published October 01, 2013

Citation: Lu Y, Chow SC, Zhang ZZ (2013) Statistical Designs for Assessing Interchangeability of Biosimilar Products. Drug Des 2:109. doi: 10.4172/2169-0138.1000109

Copyright: ? 2013 Lu Y, et al. OMICS Group - Open Access Publisher. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024